Attenuated and lethal variants of pichindé virus induce differential patterns of NF-κB activation suggesting a potential target for novel therapeutics

Gavin C. Bowick, Susan M. Fennewald, Lihong Zhang, Xianbin Yang, Judith Aronson, Robert E. Shope, Bruce A. Luxon, David G. Gorenstein, Norbert K. Herzog

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Lassa virus pathogenesis is believed to involve dysregulation of cytokines. We have previously shown nuclear factor-κB (NF-κB) inhibition using a BSL-2 model for Lassa fever. Here we further define the potential mechanism for NF-κB inhibition as involving increased levels of repressive p50/p50 homodimers, and suggest a novel therapeutic strategy that acts via modulation of host signaling.

Original languageEnglish (US)
Pages (from-to)457-462
Number of pages6
JournalViral Immunology
Volume22
Issue number6
DOIs
StatePublished - Dec 1 2009

Fingerprint

Lassa Fever
Lassa virus
Cytokines
Viruses
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Molecular Medicine

Cite this

Attenuated and lethal variants of pichindé virus induce differential patterns of NF-κB activation suggesting a potential target for novel therapeutics. / Bowick, Gavin C.; Fennewald, Susan M.; Zhang, Lihong; Yang, Xianbin; Aronson, Judith; Shope, Robert E.; Luxon, Bruce A.; Gorenstein, David G.; Herzog, Norbert K.

In: Viral Immunology, Vol. 22, No. 6, 01.12.2009, p. 457-462.

Research output: Contribution to journalArticle

Bowick, Gavin C. ; Fennewald, Susan M. ; Zhang, Lihong ; Yang, Xianbin ; Aronson, Judith ; Shope, Robert E. ; Luxon, Bruce A. ; Gorenstein, David G. ; Herzog, Norbert K. / Attenuated and lethal variants of pichindé virus induce differential patterns of NF-κB activation suggesting a potential target for novel therapeutics. In: Viral Immunology. 2009 ; Vol. 22, No. 6. pp. 457-462.
@article{662a6d09775148d9a1372349ac56cd92,
title = "Attenuated and lethal variants of pichind{\'e} virus induce differential patterns of NF-κB activation suggesting a potential target for novel therapeutics",
abstract = "Lassa virus pathogenesis is believed to involve dysregulation of cytokines. We have previously shown nuclear factor-κB (NF-κB) inhibition using a BSL-2 model for Lassa fever. Here we further define the potential mechanism for NF-κB inhibition as involving increased levels of repressive p50/p50 homodimers, and suggest a novel therapeutic strategy that acts via modulation of host signaling.",
author = "Bowick, {Gavin C.} and Fennewald, {Susan M.} and Lihong Zhang and Xianbin Yang and Judith Aronson and Shope, {Robert E.} and Luxon, {Bruce A.} and Gorenstein, {David G.} and Herzog, {Norbert K.}",
year = "2009",
month = "12",
day = "1",
doi = "10.1089/vim.2009.0034",
language = "English (US)",
volume = "22",
pages = "457--462",
journal = "Viral Immunology",
issn = "0882-8245",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Attenuated and lethal variants of pichindé virus induce differential patterns of NF-κB activation suggesting a potential target for novel therapeutics

AU - Bowick, Gavin C.

AU - Fennewald, Susan M.

AU - Zhang, Lihong

AU - Yang, Xianbin

AU - Aronson, Judith

AU - Shope, Robert E.

AU - Luxon, Bruce A.

AU - Gorenstein, David G.

AU - Herzog, Norbert K.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Lassa virus pathogenesis is believed to involve dysregulation of cytokines. We have previously shown nuclear factor-κB (NF-κB) inhibition using a BSL-2 model for Lassa fever. Here we further define the potential mechanism for NF-κB inhibition as involving increased levels of repressive p50/p50 homodimers, and suggest a novel therapeutic strategy that acts via modulation of host signaling.

AB - Lassa virus pathogenesis is believed to involve dysregulation of cytokines. We have previously shown nuclear factor-κB (NF-κB) inhibition using a BSL-2 model for Lassa fever. Here we further define the potential mechanism for NF-κB inhibition as involving increased levels of repressive p50/p50 homodimers, and suggest a novel therapeutic strategy that acts via modulation of host signaling.

UR - http://www.scopus.com/inward/record.url?scp=71449089458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71449089458&partnerID=8YFLogxK

U2 - 10.1089/vim.2009.0034

DO - 10.1089/vim.2009.0034

M3 - Article

C2 - 19951183

AN - SCOPUS:71449089458

VL - 22

SP - 457

EP - 462

JO - Viral Immunology

JF - Viral Immunology

SN - 0882-8245

IS - 6

ER -